[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].
Identifieur interne : 000081 ( Main/Exploration ); précédent : 000080; suivant : 000082[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].
Auteurs : O. Glehen [France] ; V. Kepenekian [France] ; O. Bouché [France] ; L. Gladieff [France] ; C. Honore [France]Source :
- Journal de chirurgie viscerale [ 1878-786X ] ; 2020.
Abstract
The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.
DOI: 10.1016/j.jchirv.2020.04.011
PubMed: 32328206
PubMed Central: PMC7177067
Affiliations:
- France
- Auvergne-Rhône-Alpes, Champagne-Ardenne, Grand Est, Midi-Pyrénées, Occitanie (région administrative), Rhône-Alpes
- Lyon, Pierre-Bénite, Reims, Toulouse, Villejuif
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].</title><author><name sortKey="Glehen, O" sort="Glehen, O" uniqKey="Glehen O" first="O" last="Glehen">O. Glehen</name><affiliation wicri:level="3"><nlm:affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Pierre-Bénite</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 3738, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 3738, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Kepenekian, V" sort="Kepenekian, V" uniqKey="Kepenekian V" first="V" last="Kepenekian">V. Kepenekian</name><affiliation wicri:level="3"><nlm:affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Pierre-Bénite</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 3738, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 3738, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bouche, O" sort="Bouche, O" uniqKey="Bouche O" first="O" last="Bouché">O. Bouché</name><affiliation wicri:level="3"><nlm:affiliation>Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L" last="Gladieff">L. Gladieff</name><affiliation wicri:level="3"><nlm:affiliation>Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Honore, C" sort="Honore, C" uniqKey="Honore C" first="C" last="Honore">C. Honore</name><affiliation wicri:level="3"><nlm:affiliation>Département de chirurgie, institut Gustave-Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de chirurgie, institut Gustave-Roussy, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32328206</idno><idno type="pmid">32328206</idno><idno type="doi">10.1016/j.jchirv.2020.04.011</idno><idno type="pmc">PMC7177067</idno><idno type="wicri:Area/Main/Corpus">001616</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001616</idno><idno type="wicri:Area/Main/Curation">001616</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001616</idno><idno type="wicri:Area/Main/Exploration">001616</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].</title><author><name sortKey="Glehen, O" sort="Glehen, O" uniqKey="Glehen O" first="O" last="Glehen">O. Glehen</name><affiliation wicri:level="3"><nlm:affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Pierre-Bénite</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 3738, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 3738, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Kepenekian, V" sort="Kepenekian, V" uniqKey="Kepenekian V" first="V" last="Kepenekian">V. Kepenekian</name><affiliation wicri:level="3"><nlm:affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Pierre-Bénite</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 3738, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 3738, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bouche, O" sort="Bouche, O" uniqKey="Bouche O" first="O" last="Bouché">O. Bouché</name><affiliation wicri:level="3"><nlm:affiliation>Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L" last="Gladieff">L. Gladieff</name><affiliation wicri:level="3"><nlm:affiliation>Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Honore, C" sort="Honore, C" uniqKey="Honore C" first="C" last="Honore">C. Honore</name><affiliation wicri:level="3"><nlm:affiliation>Département de chirurgie, institut Gustave-Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de chirurgie, institut Gustave-Roussy, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal de chirurgie viscerale</title><idno type="ISSN">1878-786X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32328206</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1878-786X</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal de chirurgie viscerale</Title><ISOAbbreviation>J Chir Visc</ISOAbbreviation></Journal><ArticleTitle>[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].</ArticleTitle><Pagination><MedlinePgn>S25-S32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchirv.2020.04.011</ELocationID><Abstract><AbstractText>The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.</AbstractText><CopyrightInformation>© 2020 Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glehen</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA 3738, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kepenekian</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA 3738, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouché</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladieff</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honore</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Département de chirurgie, institut Gustave-Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RENAPE-BIG-RENAPE</CollectiveName></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Chir Visc</MedlineTA><NlmUniqueID>101530148</NlmUniqueID><ISSNLinking>1878-786X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Peritoneal metastases</Keyword><Keyword MajorTopicYN="N">Primary peritoneal tumor</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Abba</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abboud</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arvieux</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakrin</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delhorme</LastName><ForeName>J-B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durand-Fontanier</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eveno</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontaine</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goere</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guyon</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefevre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lo Dico</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchal</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadeau</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezet</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pocard</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rousset</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sgarbura</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taibi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuech</LastName><ForeName>J-J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>You</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villeneuve</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32328206</ArticleId><ArticleId IdType="doi">10.1016/j.jchirv.2020.04.011</ArticleId><ArticleId IdType="pii">S1878-786X(20)30099-1</ArticleId><ArticleId IdType="pmc">PMC7177067</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
</PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Champagne-Ardenne</li><li>Grand Est</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li><li>Pierre-Bénite</li><li>Reims</li><li>Toulouse</li><li>Villejuif</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Glehen, O" sort="Glehen, O" uniqKey="Glehen O" first="O" last="Glehen">O. Glehen</name></region><name sortKey="Bouche, O" sort="Bouche, O" uniqKey="Bouche O" first="O" last="Bouché">O. Bouché</name><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L" last="Gladieff">L. Gladieff</name><name sortKey="Glehen, O" sort="Glehen, O" uniqKey="Glehen O" first="O" last="Glehen">O. Glehen</name><name sortKey="Honore, C" sort="Honore, C" uniqKey="Honore C" first="C" last="Honore">C. Honore</name><name sortKey="Kepenekian, V" sort="Kepenekian, V" uniqKey="Kepenekian V" first="V" last="Kepenekian">V. Kepenekian</name><name sortKey="Kepenekian, V" sort="Kepenekian, V" uniqKey="Kepenekian V" first="V" last="Kepenekian">V. Kepenekian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000081 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000081 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32328206
|texte= [Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32328206" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |